Astria Therapeutics (ATXS) AI Stock Analysis

• Market Cap: $321.68M
• Dividend Yield: N/A
• Average Volume (3M): 251.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.83
• Revenue Growth: N/A
• EPS Growth: 27.92%
• Country: US
• Employees: 78
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -1.69
• Shares Outstanding: 56,434,220
• 10 Day Avg. Volume: 267,513
• 30 Day Avg. Volume: 251,313
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -5.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $26.29
• Price Target Upside: 361.23% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

Astria Therapeutics displays financial stability with a strong balance sheet but faces significant risks due to zero revenue and increasing losses. The technical indicators show downward momentum. Promising developments in its drug pipeline and strategic corporate actions provide some optimism, balancing out the speculative nature of its stock.

Positive Factors

Clinical Development

The initiation of the Phase 3 ALPHA-ORBIT trial with navenibart for hereditary angioedema (HAE) presents a promising prophylactic therapy.

Financial Position

Astria ended the quarter financially strong with $328.1 million in cash, which management believes will be sufficient to fund its current operating plan into mid-2027.

Treatment Efficacy

The efficacy profile of navenibart with regard to attack rate reduction, along with the long-term dosing potential, places the asset on par if not exceeding competitor HAE prophylactic treatment options.

Negative Factors

Cash Burn

Annualized cash burn is significant, with a burn rate of $117 million and approximately 2.5 years of cash remaining.

Valuation Concerns

Analyst's recommendation is that ATXS's valuation underappreciates the opportunity of navenibart in HAE, which could be the preferred prophylactic regimen.

Astria Therapeutics Business Overview & Revenue Model

Company Description

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

How the Company Makes Money

Astria Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments, and potential royalties on sales of successfully developed drugs. Additionally, Astria Therapeutics may receive funding through grants and research collaborations. The company's revenue model typically involves significant investment in research and development, with potential returns materializing upon regulatory approval and market launch of its therapies.

Astria Therapeutics Financial Statement Overview

Summary

Astria Therapeutics has zero revenue and increasing net losses typical of a biotech in development. Despite a strong balance sheet with low leverage, ongoing cash outflows and lack of revenue highlight financial risks.

Income Statement

Astria Therapeutics has consistently reported zero revenue over the years, reflecting its pre-revenue stage typical for biotechnology firms. The net losses have increased, with the net income showing a decline from -$26.2M in 2019 to -$94.3M in 2024. The lack of revenue and increasing losses limit the assessment of profitability and growth metrics, resulting in a lower score.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, indicating a solid financial structure. The debt-to-equity ratio remains low due to minimal debt, demonstrating conservative leverage. However, the lack of revenue generation could pose future financial risks if cash reserves diminish without revenue inflow.

Cash Flow

Astria Therapeutics has negative operating cash flow, which is expected in a pre-revenue biotech company. Despite the negative free cash flow, the company has managed cash inflow through financing activities, maintaining adequate cash reserves. The operating cash flow to net income ratio suggests challenges in generating cash relative to reported net losses.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00
	EBIT
-111.56M	-83.03M	-53.50M	-194.98M	-37.44M
	EBITDA
-111.56M	-83.03M	-53.50M	-194.98M	-37.44M
	Net Income Common Stockholders
-94.26M	-72.89M	-50.16M	-30.17M	-37.06M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
328.13M	246.53M	226.44M	125.51M	44.93M
	Total Assets
342.36M	254.67M	230.63M	127.51M	47.46M
	Total Debt
5.35M	329.00K	939.00K	365.00K	1.05M
	Net Debt
-54.47M	-175.20M	-19.59M	-86.14M	-23.88M
	Total Liabilities
23.10M	11.55M	9.42M	5.20M	6.79M
	Stockholders Equity
319.26M	243.12M	221.22M	122.31M	40.67M
Cash Flow		Free Cash Flow
-81.54M	-68.47M	-43.62M	-30.17M	-32.52M
	Operating Cash Flow
-81.21M	-68.44M	-43.53M	-30.15M	-32.48M
	Investing Cash Flow
-191.86M	135.05M	-167.13M	-12.55M	6.30M
	Financing Cash Flow
157.20M	88.40M	144.72M	104.28M	40.86M

Astria Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXS, the sentiment is Negative. The current price of 5.7 is below the 20-day moving average (MA) of 6.31, below the 50-day MA of 6.82, and below the 200-day MA of 9.62, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 33.36 is Neutral, neither overbought nor oversold. The STOCH value of 16.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATXS.

Astria Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATXS	51 Neutral	$321.68M	―	-33.52%	―	―	27.92%
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	17.48%	1.17%
CRSP	46 Neutral	$3.17B	―	-19.20%	―	-89.95%	-123.71%
SGMO	41 Neutral	$184.26M	―	-187.83%	―	-67.20%	64.66%
PRQR	41 Neutral	$147.30M	―	-43.72%	―	190.40%	7.54%
EDIT	39 Underperform	$103.72M	―	-98.10%	―	-58.64%	-40.05%
NTLA	39 Underperform	$835.39M	―	-54.00%	―	59.55%	3.09%

Astria Therapeutics Corporate Events

Astria Therapeutics Unveils Phase 3 Trial for Navenibart

Astria Therapeutics has announced the design of the ALPHA-ORBIT Phase 3 clinical trial for navenibart, a treatment for hereditary angioedema, which will feature both every 3- and 6-month treatment arms. This trial aims to support global registration and is expected to initiate in Q1 2025. The company is pioneering flexible dosing options to potentially make navenibart a market-leading choice for HAE therapy, and the trial design incorporates feedback from regulatory authorities and collaboration with patients and physicians.